Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 2
1997 2
1998 2
1999 9
2000 4
2002 7
2003 5
2004 2
2005 5
2006 10
2007 5
2008 10
2009 9
2010 12
2011 15
2012 19
2013 17
2014 13
2015 24
2016 19
2017 19
2018 14
2019 18
2020 20
2021 28
2022 9
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
Saura-Esteller J, de Jong M, King LA, Ensing E, Winograd B, de Gruijl TD, Parren PWHI, van der Vliet HJ. Saura-Esteller J, et al. Among authors: de gruijl td. Front Immunol. 2022 Jun 16;13:915837. doi: 10.3389/fimmu.2022.915837. eCollection 2022. Front Immunol. 2022. PMID: 35784326 Free PMC article. Review.
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J, den Otter LAS, Bleeker MCG, Samuels SS, Heeren AM, Roemer MGM, Kenter GG, Zijlmans HJMAA, van Trommel NE, de Gruijl TD, Jordanova ES. Rotman J, et al. Among authors: de gruijl td. Front Immunol. 2020 Dec 17;11:596825. doi: 10.3389/fimmu.2020.596825. eCollection 2020. Front Immunol. 2020. PMID: 33424844 Free PMC article.
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA, Toffoli EC, Veth M, Iglesias-Guimarais V, Slot MC, Amsen D, van de Ven R, Derks S, Fransen MF, Tuynman JB, Riedl T, Roovers RC, Adang AEP, Ruben JM, Parren PWHI, de Gruijl TD, van der Vliet HJ. King LA, et al. Among authors: de gruijl td. Cancer Immunol Res. 2023 Sep 1;11(9):1237-1252. doi: 10.1158/2326-6066.CIR-23-0189. Cancer Immunol Res. 2023. PMID: 37368791
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM. van den Ende T, et al. Among authors: de gruijl td. Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504550 Clinical Trial.
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
van den Ende T, Ezdoglian A, Baas LM, Bakker J, Lougheed SM, Harrasser M, Waasdorp C, van Berge Henegouwen MI, Hulshof MCCM, Haj Mohammad N, van Hillegersberg R, Mook S, van der Laken CJ, van Grieken NCT, Derks S, Bijlsma MF, van Laarhoven HWM, de Gruijl TD. van den Ende T, et al. Among authors: de gruijl td. Oncoimmunology. 2023 Jul 17;12(1):2233403. doi: 10.1080/2162402X.2023.2233403. eCollection 2023. Oncoimmunology. 2023. PMID: 37470057 Free PMC article.
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, de Weerdt I, Kater AP, Zweegman S, Horbach S, Riedl T, Winograd B, Roovers RC, Adang AEP, de Gruijl TD, Parren PWHI, van der Vliet HJ. Lameris R, et al. Among authors: de gruijl td. Cell Rep Med. 2023 Mar 21;4(3):100961. doi: 10.1016/j.xcrm.2023.100961. Epub 2023 Mar 2. Cell Rep Med. 2023. PMID: 36868236 Free PMC article.
Immune-competent human skin disease models.
Bergers LIJC, Reijnders CMA, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, Gibbs S. Bergers LIJC, et al. Among authors: de gruijl td. Drug Discov Today. 2016 Sep;21(9):1479-1488. doi: 10.1016/j.drudis.2016.05.008. Epub 2016 Jun 2. Drug Discov Today. 2016. PMID: 27265772 Review.
Apoptotic vesicles as tumor vaccine.
Horrevorts SK, Garcia-Vallejo JJ, van Vliet SJ, van de Loosdrecht AA, van Kooyk Y, de Gruijl TD. Horrevorts SK, et al. Among authors: de gruijl td. Immunotherapy. 2016;8(1):5-8. doi: 10.2217/imt.15.96. Epub 2015 Dec 7. Immunotherapy. 2016. PMID: 26641072 No abstract available.
From simplicity to complexity in current melanoma models.
Michielon E, de Gruijl TD, Gibbs S. Michielon E, et al. Among authors: de gruijl td. Exp Dermatol. 2022 Dec;31(12):1818-1836. doi: 10.1111/exd.14675. Epub 2022 Oct 5. Exp Dermatol. 2022. PMID: 36103206 Free PMC article. Review.
Pancreatic Cancer and Immunotherapy: A Clinical Overview.
Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ, de Gruijl TD. Timmer FEF, et al. Among authors: de gruijl td. Cancers (Basel). 2021 Aug 17;13(16):4138. doi: 10.3390/cancers13164138. Cancers (Basel). 2021. PMID: 34439292 Free PMC article. Review.
286 results